Dr. Paul H. Sugarbaker

Dr. Paul H. Sugarbaker

Surgical Oncologist & Contributing Writer

Surgical oncologist Dr. Paul H. Sugarbaker at MedStar Washington Hospital Center is recognized as the world’s leading expert on peritoneal mesothelioma cancer. He pioneered the innovative surgical techniques that changed the way the cancer is treated today.

About Dr. Paul H. Sugarbaker

Accreditations
  • American Board of Surgery

  • American Society of Abdominal Surgeons

  • Cornell University Medical College

Fast Facts
  • Sugarbaker has published more than 1,000 scientific articles and book chapters, along with numerous medical textbooks. He is editor and co-author of “Cytoreductive Surgery and Perioperative Chemotherapy for Peritoneal Surface Malignancy.”

  • He spent 10 years as a senior surgeon at the National Institutes of Health, National Cancer Institute, before joining Washington Cancer Institute at MedStar Washington Hospital Center in 1989.

  • He has performed more than 1,500 cytoreductive surgery/hyperthermic intraperitoneal chemotherapy combination procedures for patients with gastrointestinal cancer, gynecologic malignancy and peritoneal mesothelioma.

Dr. Sugarbaker is chief of the Peritoneal Surface Malignancy Program and director of the Center for Gastrointestinal Malignancies at the MedStar Washington Hospital Center in Washington, D.C. He is the general secretary for the Peritoneal Surface Oncology Group International (PSOGI). This is an effort to develop treatment centers for peritoneal metastases and mesothelioma around the globe.

Sugarbaker has been the driving force behind the development of the cytoreductive surgery/hyperthermic intraperitoneal chemotherapy procedure that specialists are using today to effectively treat peritoneal mesothelioma.

Many of his colleagues refer to it as the “Sugarbaker Procedure,” which has become the standard treatment for several abdominal cancers that spread to the surfaces of the abdomen and pelvis.

The procedure has been credited with extending the lives of peritoneal mesothelioma patients, giving hope to those with this aggressive cancer who once had none. The 10-year survival rate of his most recent group of 36 surgical patients was 75%.

As an international expert on surgical oncology, Sugarbaker has lectured extensively, both within the U.S. and abroad, helping those around the world.

“He is a tireless innovator and one of the legends of our time,” said Dr. Brendan Moran, surgical oncologist at the Peritoneal Malignancy Institute at Basingstoke Hospital in the U.K. “I consider Paul Sugarbaker the global leader in surgical oncology.”

Share this article

Last Modified September 4, 2020

Get Your Free Mesothelioma Guide Chat live with a patient advocate now